Effect of Mandibular Advancement through Oral Appliance Therapy on Quality of Life in Obstructive Sleep Apnea: A Scoping Review

Nisha Kalonia1, Pradeep Raghav2, Kumar Amit3, Prashant Sharma4

Abstract
Purpose: The scoping review was conducted for the evaluation of effect of mandibular advancement through oral appliance therapy on quality of life in obstructive sleep apnea (OSA).

Methods: Strategic and thorough literature search using free text and MESH terms in three major database systems PubMed, SCOPUS, and Web of Science was undertaken till October 30, 2020, followed by PRISMA for the identification of studies for data extraction.

Results and conclusions: Summarization of evidence was done for study characteristics, and diagnostic methods for the evaluation of effect of mandibular advancement through oral appliance therapy on quality of life in OSA. The literature supports that patients using mandibular advancement appliances (MADs) showed better adherence and compliance in comparison with those using continuous positive airway pressure (CPAP); along with the patients’ compliance, the daytime sleepiness, state on waking, morning headache, oxygen saturation, frequency and intensity of snoring, and quality of sleep for both patients and their bed partners showed a marked improvement with MAD.

Keywords: Health status, MAD, Obstructive sleep apnea, Oral appliance, Quality of life, Scoping review.

Indian Journal of Sleep Medicine (2021): 10.5005/jp-journals-10069-0088

Introduction
Recurrence of partial or complete upper airway obstruction during sleep leads to variable symptoms such as excessive daytime sleepiness,1 snoring, gasping, snorting, insomnia, nocturia, bedwetting, memory loss or concentration issues, mood swings, irritation, and decreased libido.2

According to the Sleep Heart Health Study, the increased risk of moderate to severe obstructive sleep apnea (OSA) was 20% in blacks and 23% in American Indians compared with that of whites, that is, 17%.2

Higher risk for OSA was found in men than in women, even once women reach menopause risk for OSA increases similar in percentage to men.2 The risk of OSA increases with age, and this may be due to a reduction in slow-wave sleep with age (i.e., deep sleep), which is a protective mechanism against sleep-disordered breathing and collapse of airway.

Comorbid conditions associated with OSA include stroke, hypertension, hyperlipidemia, myocardial infarction, glucose intolerance, diabetes, pulmonary hypertension, congestive heart failure, arrhythmias including atrial fibrillation, and depression. Patients suffering from moderate or severe OSA are at higher risk for these conditions.2

To assess the risk of OSA among the population, different questionnaires have been formulated, and the proposed notable ones among them are Berlin questionnaire (BQ), used in the setting for primary care, and the STOP-Bang Questionnaire, for the screening of preoperative procedures. The Epworth sleepiness scale (ESS) is used to assess sleepiness in both clinical practices and research work.

If clinically it is evaluated as OSA, it requires overnight testing for confirmatory diagnosis. The polysomnography (PSG) is the standard diagnostic test, in which monitoring of both sleep parameters and respiratory parameters is done. Behavioral modification measures, medical devices, and surgery are the treatments for OSA.3

Behavioral modifications include regular aerobic exercise, weight loss abstinence from alcohol, and not to sleep in supine position. In patients suffering from positional OSA [i.e., elevated apnea hypopnea index (AHI) predominantly in the supine position], avoid sleeping to the side or sleeping in prone position is the treatment. Other factors associated with improvement in severity of OSA are lifestyle interventions, bariatric surgery, and weight loss medication.3

Primary therapy for individuals with symptomatic OSA of any severity is continuous positive airway pressure (CPAP) as it keeps the upper airway patent during sleep. However, on a long-term basis, there is difficulty in patient tolerance and compliance to this treatment. Oral appliances have been proposed as an alternative...
method to CPAP therapy. They are designed in such a way so that the upper airway is kept open by either forward advancement of the lower jaw or by keeping the mouth open during sleep.\(^1\) Thus, OAs can be offered as alternate therapies due to side effects or inability to use CPAP.\(^4\)

Therefore, this scoping review was conducted to evaluate the “Effect of mandibular advancement through oral appliance therapy on quality of life in obstructive sleep apnea (OSA)”.\(^5\)

**Search Strategy and Selection Criteria**

The scoping review was conducted to evaluate the “Effect of mandibular advancement through oral appliance therapy on quality of life in obstructive sleep apnea (OSA)”. Considering the effect of oral appliances on the quality of life in OSA patients, this review included the publications that hold the search terms that were searched up till October 30, 2020. The PRISMA search strategy was prepared using the MESH terms and Boolean terminology: ((obstructive AND sleep AND (apnoea OR apnea)) OR (sleep AND breathing AND disorder’ OR respiratory AND disorder’)) OR “sleep-disordered breathing”) AND (“Orthodontic Appliances” OR (oral OR dental OR (mandib\(^1\) AND (advancement OR repositioning’))) AND (device’ OR appliance’ OR splint) AND (“quality of life” OR qol OR “health status” OR “functional status” OR “self rated health” OR “self perceived health” OR rhp OR “SF-36 mental component” OR “SF-36 physical component” OR “FOSQ” OR “EuroQol” OR “SAQLI”). This search strategy was applied to the PUBMED, SCOPUS, and WEB OF SCIENCE databases. All types of studies are included. Using PICO (participants, intervention, comparator, and outcome) criteria, data extraction was done by two researchers individually, and discordance was addressed by the third researcher. Thorough screening of included articles was done, and the level of evidence was determined based on Oxford Centre for Evidence-based Medicine (OCEBM) (Table 1).

### Table 1: Oxford Centre for Evidence-based Medicine 2011 Levels of Evidence

| Question | Step 1 (Level 1\(^\dagger\)) | Step 2 (Level 2\(^\dagger\)) | Step 3 (Level 3\(^\dagger\)) | Step 4 (Level 4\(^\dagger\)) | Step 5 (Level 5\(^\dagger\)) |
|----------|---------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| How common is the problem? | Local and current random sample surveys (or censuses) | Systematic review of surveys that allow matching to local circumstances\(^\dagger\) | Local non-random sample\(^\dagger\) | Case-series\(^\dagger\) | n/a |
| Is this diagnostic or monitoring test accurate? (Diagnosis) | Systematic review of cross-sectional studies with consistently applied reference standard and blinded | Individual cross-sectional studies with consistently applied reference standard and blinded | Non-consecutive studies, or studies without consistently applied reference standards\(^\dagger\) | Case-control studies, or “poor or non-independent reference standard” | Mechanism-based reasoning |
| What will happen if we do not add a therapy? (Prognosis) | Systematic review of inception cohort studies | Inception cohort studies | Cohort study or control arm of randomized trial\(^\dagger\) | Case-series or case-control studies, or poor quality prognostic cohort study | n/a |
| Does this intervention help? (Treatment Benefits) | Systematic review of randomized trials or n-of-1 trials | Randomized trial or observational study with dramatic effect | Non-randomized controlled cohort/follow-up study\(^\dagger\) | Case-series, case-control studies, or historically controlled studies\(^\dagger\) | Mechanism-based reasoning |
| What are the COMMON harms? (Treatment Harms) | Systematic review of randomized trials, systematic review of nested case-control studies, n-of-1 trial with the patient you are raising the question about, or observational study with dramatic effect | Individual randomized trial or (exceptionally) observational study with dramatic effect | Non-randomized controlled cohort/follow-up study (post-marketing surveillance) provided there are sufficient numbers to rule out a common harm. (For long-term harms the duration of follow-up must be sufficient)\(^\dagger\) | Case-series, case-control, or historically controlled studies\(^\dagger\) | Mechanism-based reasoning |
| What are the RARE harms? (Treatment Harms) | Systematic review of randomized trials or n-of-1 trial | Randomized trial or (exceptionally) observational study with dramatic effect | Non-randomized controlled cohort/follow-up study** | Case-series, case-control, or historically controlled studies** | Mechanism-based reasoning |
| Is this (early detection) test worthwhile? (Screening) | Systematic review of randomized trials | Randomized trial | Non-randomized controlled cohort/follow-up study** | Case-series, case-control, or historically controlled studies** | Mechanism-based reasoning |

\(^\dagger\)Level may be graded down on the basis of study quality, imprecision, indirectness (study PICO does not match questions PICO), because of inconsistency between studies, or because the absolute effect size is very small; Level may be graded up if there is a large or very large effect size.

\(^\dagger\)As always, a systematic review is generally better than an individual study.

How to cite the Levels of Evidence Table

OCEBM Levels of Evidence Working Group\(^6\). “The Oxford 2011 Levels of Evidence”. Oxford Centre for Evidence-based Medicine. http://www.cebm.net/index.aspx?o=5653

\(^6\)OCEBM Table of Evidence Working Group = Jeremy Howick, Iain Chalmers (James Lind Library), Paul Glasziou, Trish Greenhalgh, Carl Heneghan, Alessandro Liberati, Ivan Moschetti, Bob Phillips, Hazel Thornton, Olive Goddard and Mary Hodgkinson
Results
Study Selection
A total of 3,202 articles were determined through search strategy and sources listed previously. After the removal of duplicates, 1,013 articles remained. After the titles had been screened, a total of 937 articles were excluded as they were not matching the search question. After the screening of abstracts, 10 articles were excluded as they had no relation to orthodontic appliance therapy, not explaining the quality of life, and were not in the English language. The remaining 66 articles were completely evaluated for the text, out of which 28 articles were excluded as they had no relation to oral appliance therapy, not explaining the quality of life, included surgical intervention, and were not in the English language. Finally, 38 articles were included in the review (Flowchart 1).

Study Characteristics
Summarized methodological data and study results are mentioned in Table 2. The included articles were in English and published between 2011 and 2020. The articles included were on mandibular advancement appliances (MAD); comparison between the different designs of MAD; the effect of orthodontic appliances on temporomandibular joint (TMJ) and stomatognathic system; and comparison between positional therapy, CPAP, and oral appliances with their effects on quality of life. There were three pilot studies, one longitudinal follow-up study, one case–control study, two nonrandomized prospective studies, two prospective observational studies, one prospective study, three cohort studies, four clinical trials, 13 randomized controlled trials, one review article, four systematic reviews, and meta-analysis, and three network meta-analysis.

Discussion
This scoping review aimed to analyze the effectiveness, efficacy, different design features, side effects of the appliance, and patient selection for MAD therapy. Targeted symptoms are sleepiness, snoring, quality of life, and possible comorbidities. In this study, the outcomes were evaluated by AHI, ESS, lowest oxygen saturation level, ODI, QD2A depression score, BQ variable, FOSQ, SF-36 physical component summary and mental component summary, QSO, Pichot score, Pittsburg sleep quality index (PSQI), home sleep apnea test (HSAT), KIIEF-5, and SAQLI scores to check the effectiveness of MADs.

Different levels of evidence studies were selected to answer the clinical question proposed in this scoping review, and different studies used different designs of MADs. These were AT-MAD, elastomer appliance with an adjustable Herbst mechanism, titratable PAT-MAD, custom-made Narval MRDs, monoblock, and SILENT NITE appliances, TAP3, KLEARWAY, thermoplastic heat-molded titratable MAD, self-molded bespoke, semi-bespoke, and fully bespoke MAD.

According to the studies conducted by Banhiran et al. and Agarwal et al., it was concluded that MAA resulted in a statistically significant reduction of baseline AHI index and the subjective outcomes with ESS scores (snoring intensity and frequency, and daytime sleepiness). The first study conducted among Asians by Banhiran et al. demonstrated that an AT-MAD, if done properly, had good outcomes including improved quality of life (QOL) with a short-term treatment. Its advantages were cost-effectiveness and readily available. The continuous wearing of OAs reduces the AHI from severe to mild or moderate OSA along with the reduction of incidence of systemic complication and improvement in the life quality of the patients.

Follow-up studies by Attali et al. and Vecchierini et al. stated that libido disorders and polyuria resolved in 81 and 64% of the participants, respectively, and there was a significant improvement in visual analog scale scores for sleep, morning headache, and state on waking ($p < 0.0001$) during MRD therapy.

Further, the effectiveness and efficacy of thermoplastic and custom-made MAD appliances were compared; various studies concluded that the titratable thermoplastic MAD is more efficacious in reducing SDB and associated symptoms in patients with mild to severe OSA and the effectiveness was the same for severity of symptoms, quality of life, and in reducing blood pressure but the
Effect of Mandibular Advancement through Oral Appliance Therapy

Table 2: Synopsis of the effect of mandibular advancement through oral appliance therapy on quality of life in obstructive sleep apnea (OSA)

| Sl. No. | Outcomes | Results significant to the research topic |
|---------|----------|-----------------------------------------|
| 1       | AHI Index, AI, HI | Decreased AHI<sup>5,9,17,14–33</sup><br>Decreased AI<sup>13,22–24</sup><br>Decreased HI<sup>2,23</sup> |
| 2       | Respiratory Disturbance Index (RDI) | No effect<sup>36</sup> |
| 3       | Epworth Sleepiness Scale (ESS) | Overall decreased<sup>5–7,11–13,15,16,20,22,24,25,27,28,30,34,35,37</sup><br>Improved daytime sleepiness<sup>5,9,14,18,21,38</sup><br>Improved neurobehavioral outcome<sup>17,26</sup><br>Improved snoring, daytime sleepiness<sup>25</sup><br>Arousal index<sup>29</sup> |
| 4       | Oxygen saturation (SpO₂) | Increased<sup>15,17,24,30–32,39</sup><br>No significant effect<sup>6</sup> |
| 5       | SaO₂ nadir (lowest oxygen saturation) | Increased<sup>15,16,18,31,34,39</sup><br>Decreased<sup>26</sup> |
| 6       | Oxygen Desaturation Index (ODI) | Decreased<sup>7,9,22,31,35,39,40</sup> |
| 7       | Sleep Apnea Quality of Life Index (SAQLI) | Alleviated symptoms (Domain D)<sup>16</sup><br>Decreased<sup>6,27,36</sup> |
| 8       | Subjective symptoms: Snoring, daytime sleepiness, and night sleep quality | Improved snoring, daytime sleepiness and night sleep quality<sup>39</sup><br>Improved snoring, daytime sleepiness<sup>19,22</sup><br>improved snoring<sup>15</sup><br>Reduced snoring loudness, frequency, tiredness after sleeping, breathing pauses<sup>11,38</sup> |
| 9       | BQ variables | Improved symptoms of depression<sup>3,22</sup><br>Improved depression rate<sup>20</sup> |
| 10      | Pichot QD2A depression score | Improved neurobehavioral outcome<sup>17</sup><br>Improved daytime sleepiness<sup>18</sup><br>Increased except general productivity & social outcome<sup>6</sup><br>Overall improved (increased)<sup>12,14,15,22,26–29,31,37</sup> |
| 11      | Hospital anxiety and depression (HAD) scale | No improvement in sexual activity<sup>17</sup><br>Increased<sup>12,15,26,30,31,37,41</sup> |
| 12      | Functional outcomes of sleep quality (FOSQ score) | Increased<sup>15,32</sup><br>Increased<sup>18</sup> |
| 13      | FOSQ-SE | Decreased snoring loudness and frequency<sup>8,32</sup> |
| 14      | Short-form 36 (SF36) score | Decreased<sup>7,8,15,32</sup><br>Decreased<sup>22,30–32</sup> |
| 15      | SF12 score | Decreased<sup>15,32</sup><br>Increased<sup>18</sup> |
| 16      | Quebec sleep Questionnaire (QSQ) | Decreased<sup>7,8,15,32</sup><br>Decreased<sup>22,30–32</sup> |
| 17      | Visual Analog Scale | Decreased snoring loudness and frequency<sup>8,32</sup> |
| 18      | Pichot fatigue score | Decreased<sup>7,8,15,32</sup><br>Decreased<sup>22,30–32</sup> |
| 19      | Pittsburgh Sleep Quality Index (PSQI) | Decreased<sup>7,8,15,32</sup><br>Decreased<sup>22,30–32</sup> |
| 20      | DASS21 score | State of depression improved<sup>31</sup><br>Improved sleep latency<sup>33</sup> |
| 21      | MSLT | Increased<sup>23</sup> |

Side effects were comparatively more to custom-made MAD. For the patients with OSA who refused or did not tolerate the CPAP therapy, the thermoplastic heat-molded titratable MAD was demonstrated to be equivalent in the short term to the custom-made acrylic MAD.<sup>9</sup> Alessandri-Bonetti et al.<sup>10</sup> analyzed the effects of MADs on TMD in patients with and without the presence of signs and symptoms, which indicated that the evidence available was of moderate to low quality, showing that MAD therapy was not a risk factor for TMD signs and symptoms. Therefore, the TMD should not be considered an absolute contraindication for the use of MADs in the treatment of OSA.

The study by Baslas et al.<sup>11</sup> after intervention with MAD found a statistically significant difference between HbA1c level and apnea hypopnea index AHI score in all groups except HbA1c level in severe OSA patients. It was therefore concluded that MAD may be recommended for patients with OSA and T2DM. This study provided evidence to inform health workers about the possible use of MAD in OSA and T2DM. Considering the higher level of evidence, systematic review can provide excellent evidence in comparing the quality of life outcomes with other outcomes between CPAP and MAD. So the systematic reviews and meta-analysis showed that the treatment effect of CPAP was greater in the vitality dimension. The score estimates of the improvement in the vitality scale (not the other seven scales) were similar for CPAP and MADs when compared with control. There were no statistically significant differences in quality of life, cognitive function outcomes, or functional outcomes in patients using CPAP vs MAD. However, CPAP was more effective in reducing AHI compared to oral appliances. With quality of life (SF-36 score), the results showed that both CPAP and MAD had
similar improvements in mental health and physical functioning. In terms of performance results, the results showed that both CPAP and MAD improved FOSQ scores without significant statistical differences, consistent with previous review studies where MAD users showed significantly higher compliance (p = 0.004) than CPAP users.12–14

Further, it was reviewed that maintenance costs for MAD were low and relatively high for CPAP therapy, which could influence cost-effectiveness when considering long-term therapy. De Vries et al.15 compared clinical efficacy with the cost of MAD treatment with CPAP treatment in the moderate OSA, where CPAP was more effective clinically (in terms of AHI reduction) and less expensive than MAD.

Finally, to conclude, although both CPAP and MAD improved the quality of life, sleep, and performance and cognitive outcomes in patients with OSA, this review presented limited quality of evidence to suggest a significant difference in favor of CPAP in reducing AHI. Although the two therapies worked differently with the efficacy and treatment usage profiles, these results were similar in the overall performance. As effectiveness is a combination of efficacy and treatment compliance, sleep medicine specialists should monitor the use of treatment and provide patients who do not comply with CPAP orally for treatment. Choosing CPAP as the first line of treatment for patients with OSA symptoms but MAD should be considered as an appropriate alternative to reducing symptoms and improving QOL, where apnea and hypopnea are successfully reduced based on the findings of this scoping review.

The limitation of this review was that all the studies available were comparative. The designs of orthodontic appliances and the degree of titration were different in different studies. In addition, different levels of evidence studies were taken for this review, which had different limitations such as small sample size; the subjects had dropped out in between the treatment in follow-up studies; nonrandomized trials were included; along with this, there was a lack of blinding of participants and outcome in the trials.

CONCLUSION
This scoping review finally concluded that:

- There were no differences in quality of life, functional outcomes, or cognitive function outcomes in patients using CPAP and MAD.
- Patients using MAD showed better adherence and compliance as compared to CPAP; along with this, the daytime sleepiness, state on waking, morning headache, oxygen saturation, frequency and intensity of snoring, and sleep quality for both patients who snore and their bed partners showed a marked improvement with MAD.
- The effectiveness of titratable MAD thermoplastic was to reduce SDB and associated symptoms in patients with mild to severe OSA, and the efficacy was similar in both the thermoplastic and custom-made MAD machine in terms of severity, symptoms, quality of life, and reducing blood pressure.
- Side effects of oral appliances include aggravation of temporomandibular disorder (TMD) but the presence of TMD should not be considered a general objection to the use of MAD in OSA administration.
- Maintenance costs for MAD were low and relatively high for CPAP therapy, which could influence cost-effectiveness when considering long-term therapy. However, the cost per QALY was better with MAD compared to that with CPAP.

Choosing CPAP as a first-line treatment for patients with OSA symptoms but MAD should be considered an appropriate alternative to reducing symptoms and improving QOL when apnea and hypopnea are successfully reduced.

RECOMMENDATIONS
We recommend that future research projects should include appropriate randomized studies, blinding treatment groups, concealing outcome tests, robust fitness method, critical and reproductive diagnostic approach, and quality-tested studies included to reduce bias.

ORCID
Kumar Amit @ https://orcid.org/0000-0002-4265-1034

REFERENCES
1. Lim J, Lasserson TJ, Fleetham J, et al. Oral appliances for obstructive sleep apnoea. Cochrane Database Syst Rev 2006;1(2):30–45. DOI: 10.1002/14651858.CD004435.pub3.
2. Rundo JV. Obstructive sleep apnoea basics. Cleve Clin J Med 2019;86(1):2–9. DOI: 10.3949/ccjm.86.s1.02.
3. Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnoea: a review. JAMA 2020;323(14):1389–1400. DOI: 10.1001/jama.2020.3514.
4. Rama K, Dort LC, Katz SG, et al. Clinical practice guideline for the treatment of obstructive sleep apnoea and snoring with oral appliance therapy: an update for 2015: an American Academy of Sleep Medicine and American Academy of Dental Sleep Medicine clinical practice guideline. J Clin Sleep Med 2015;11(7):773–827. DOI: 10.5664/jcsm.4858.
5. Banhrihan W, Kittiphumpong W, Assanasen P, et al. Adjustable thermoplastic mandibular advancement device for obstructive sleep apnoea: outcomes and practicability. Laryngoscope 2014;124(10):2427–2432. DOI: 10.1002/lary.24607.
6. Agarwal P, Ariga P, Jain AR. Efficacy of custom-made mandibular advancement appliance on patients with obstructive sleep apnoea: a prospective clinical trial. Drug Inven Today 2018;10(6):1–7. DOI: 10.4103/0976-237X.161881.
7. Attai V, Vecchieri MF, Collet JM, et al. Efficacy and tolerability of a custom-made Narval mandibular repositioning device for the treatment of obstructive sleep apnoea: ORCADES study 2-year follow-up data. J Dent Sleep Med 2019;63(8):64–74. DOI: 10.1016/j.sleep.2015.05.020.
8. Vecchieri MF, Attai V, Collet JM, et al. A custom-made mandibular repositioning device for obstructive sleep apnoea–hypopnoea syndrome: the ORCADES study. J Dent Sleep Med 2016;19(4):131–140. DOI: 10.1016/j.sleep.2015.05.020.
9. Gagnadoux F, Nguyen XL, Le Vaillant M, et al. Comparison of titrable thermoplastic versus custom-made mandibular advancement device for the treatment of obstructive sleep apnoea. Respir Med 2017;131(1):35–42. DOI: 10.1016/j.rmed.2017.08.004.
10. Alessi-Bonetti A, Bortolotti F, Moreno-Hay l, et al. Effects of mandibular advancement device for obstructive sleep apnea on temporomandibular disorders: A systematic review and meta-analysis. Sleep Med Rev 2019;48:101211. DOI: 10.1016/j.smrv.2019.101211.
11. Baslas V, Chand P, Jurel SK, et al. A pilot study to determine the effect of three months of oral appliance therapy using a mandibular advancement device on HbA1c in subjects with Type II diabetes.
mellitus and obstructive sleep apnoea. J Prosthodont 2019;28(3):271–275. DOI: 10.1111/jopr.12973.
12. Schwartz M, Acosta L, Hung YL, et al. Effects of CPAP and mandibular advancement device treatment in obstructive sleep apnoea patients: a systematic review and meta-analysis. Sleep Breath 2018;22(3):555–568. DOI: 10.1007/s11325–017–1590–6.
13. Bratton DJ, Gaisl T, Schlatter C, et al. Comparison of the effects of continuous positive airway pressure and mandibular advancement devices on sleepiness in patients with obstructive sleep apnoea: a network meta-analysis. Lancet Respir Med 2015;3(11):869–878. DOI: 10.1016/s2213–2600(15)00416–6.
14. Zhang T, Li X, Qiao X, et al. Effect of oral appliance on reproductive system of the male New-Zealand rabbit with obstructive sleep apnoea-hypopnoea syndrome. Cranio 2018;98(38):3090–3095. DOI: 10.3760/cma.j.issn.0376–4918.2018.38.010.
15. De Vries GE, Hoekema A, Vermeulen KM, et al. Clinical-and cost-effectiveness of a mandibular advancement device versus continuous positive airway pressure in moderate obstructive sleep apnoea. J Clin Sleep Med 2019;15(10):1477–1485. DOI: 10.5664/jcsm.7980.
16. Shin HW, Park JH, Park JW, et al. Effects of surgical vs nonsurgical therapy on erectile dysfunction and quality of life in obstructive sleep apnoea syndrome: a pilot study. J Sex Med 2013;10(8):2053–2059. DOI: 10.1111/j.1743–4878.2013.03128.x.
17. Uniken Venema JA, Dhoire MH, Joffe-Sokolova D, et al. Long-term effect of mandibular advancement device and continuous positive airway pressure. J Clin Sleep Med 2020;16(3):353–359. DOI: 10.5664/jcsm.6804.
18. Fernández‐Julián E, Pérez‐Carbonell T, Marco R, et al. Impact of an oral appliance on obstructive sleep apnoea severity, quality of life, and biomarkers. Laryngoscope 2018;128(7):1720–1726. DOI: 10.1002/ lary.26913.
19. Haviy V, Bachar G, Afamian DJ, et al. A 2-year mean follow-up of oral appliance therapy for severe obstructive sleep apnoea: a cohort study. Oral Dis 2015;21(3):386–392. DOI: 10.1111/odi.12291.
20. Nerfeldt P, Friberg D. Effectiveness of oral appliances in obstructive sleep apnoea with respiratory arousals. J Clin Sleep Med 2016;12(8):1159–1165. DOI: 10.5664/jcsm.6058.
21. Schutz TC, Cunha TC, Moura-Guimaraes T, et al. Comparison of the effects of continuous positive airway pressure, oral appliance and exercise training in obstructive sleep apnoea syndrome. Clinics 2013;68(8):1168–1174. DOI: 10.6061/clinics/2013(08)17.
22. Soh L, Han HJ, Yue Y, et al. Evaluation of prefabricated adjustable thermoplastic mandibular advancement devices (Pat-Mads) for obstructive sleep apnoea: an Asian experience. J Dent Sleep Med 2020;75(3):96–102. DOI: 10.1016/j.jslp.2020.02.025.
23. Zhou J, Liu YH. A randomised crossover study comparing two mandibular repositioning appliances for treatment of obstructive sleep apnoea-hypopnoea syndrome. J Prosthet Dent 2017;118(12):96–102. DOI: 10.1016/j.jprosdent.2014.05.007.
24. Cammaroto G, Galletti C, Galletti F, et al. Mandibular advancement devices vs nasal-continuous positive airway pressure in the treatment of obstructive sleep apnoea: Systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal 2017;22(4):417–424. DOI: 10.4317/medoral.21671.
25. Phillips CL, Grunstein RR, Darendellier MA, et al. Health outcomes of continuous positive airway pressure versus oral appliance treatment for obstructive sleep apnoea: a randomised controlled trial. Am J Respir Crit Care Med 2013;187(8):879–887. DOI: 10.1164/rccm.201212-2230OC.
26. Ayda D, Singh SV, Tripathi A, et al. A pilot study to compare patient perception of obstructive sleep apnoea treatment with CPAP or oral appliance therapy. J Prosthet Dent 2014;112(5):1188–1193. DOI: 10.1016/j.prosdent.2014.05.007.
27. Eriksson EW, Leissner L, Isacsson G, et al. A prospective 10-year follow-up polygraphic study of patients treated with a mandibular protruding device. Sleep Breath 2015;19(1):393–401. DOI: 10.1007/s11325–014-1034–5.
28. Remmers JE, Topor Z, Grosse J, et al. A feedback-controlled mandibular positioner identifies individuals with sleep apnoea who will respond to oral appliance therapy. J Clin Sleep Med 2017;13(7):871–880. DOI: 10.5664/jcsm.6656.
29. Kuhn E, Schwarz EJ, Bratton DJ, et al. Effects of CPAP and mandibular advancement devices on health-related quality of life in OSA: a systematic review and meta-analysis. Sleep Med 2017;15(1):786–794. DOI: 10.1016/j.sleep.2017.01.020.
30. Zhou J, Li DH, Zhu PF, et al. Effect of mandibular advancement device on the stomatognathic system in patients with mild-to-moderate obstructive sleep apnoea-hypopnoea syndrome. J Oral Rehabil 2020;47(7):889–890. DOI: 10.1111/joor.12982.